A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study

A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid, theobromine, (T-1-PCPA). At first, we started wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Ibrahim H., Yousef, Reda G., Elkady, Hazem, Alsfouk, Aisha A., Alsfouk, Bshra A., Husein, Dalal Z., Ibrahim, Ibrahim M., Elkaeed, Eslam B., Metwaly, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867533/
https://www.ncbi.nlm.nih.gov/pubmed/36676140
http://dx.doi.org/10.3390/life13010191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867533/
https://www.ncbi.nlm.nih.gov/pubmed/36676140
http://dx.doi.org/10.3390/life13010191

Ejemplares similares